Background And Objectives: To estimate the average treatment effect on the treated (ATT) and to assess the clinical outcomes in two different types of mesh in robotic Rives-Stoppa (rRS) ventral hernia repair (VHR).
Methods: A retrospective analysis of a robotic VHR database between February 1, 2013 and May 31, 2022. Patients who underwent a rRS VHR were included in this study and separated into two groups depending on the mesh used: Synecor Preperitoneal Biomaterial (Synecor Pre) and Bard™ Soft. Through propensity score and inverse-probability-treatment-weighting, the ATT was estimated for two scenarios; the first with the treated target having used the Synecor Pre, the second having used the Bard™ Soft mesh. Adjusted linear regression models, including lingering imbalanced variables, were used for both the primary outcome of the Comprehensive Complication Index (CCI®), and the secondary outcome of the hospital cost.
Results: A total of 186 patients who underwent rRS were separated into the two groups (Synecor Pre mesh, n = 85; Bard™ Soft mesh, n = 101). Adjusted linear regression models for the CCI showed no statistical difference between both groups (p > 0.05), whereas ATT on hospital cost was significantly higher ( < 0.001) in the Synecor Pre group in both scenarios [(95% confidence interval) = 3882 (2352, 5413) and -5185 (-8213, -2157), respectively].
Conclusion: Both mesh materials provided excellent outcomes with no difference in complications or recurrence rates. However, hospital cost was found to be higher in the hybrid mesh group. Long-term follow-up is needed to fully assess the performance of both mesh types in rRS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840217 | PMC |
| http://dx.doi.org/10.4293/JSLS.2022.00071 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ventral Hernia Repair With a Hybrid Absorbable-permanent Preperitoneal Mesh.
Surg Laparosc Endosc Percutan Tech
December 2024
Department of Surgery, North Shore University Health System, Evanston, IL.
Article Synopsis
- - The study focused on evaluating the safety and effectiveness of the GORE SYNECOR Preperitoneal Biomaterial (PRE device) for ventral hernia repairs, involving a retrospective review of outcomes for 148 patients over more than a year post-surgery.
- - Results showed a low incidence of adverse events within 30 days (8.8% overall), with the main complications being surgical site infections (4.8%) and the need for reoperations (2.0%). Importantly, no hernia recurrences were reported during the study.
- - The findings suggest that the PRE device is both safe and effective for complex repairs, combining the benefits of absorbable and permanent mesh materials when placed in the retromuscular
Comparison of Hybrid Versus Synthetic Mesh in Robotic Rives-Stoppa Ventral Hernia Repair.
JSLS
February 2023
Department of Surgery, Good Samaritan Medical Center, Brockton, MA.
Background And Objectives: To estimate the average treatment effect on the treated (ATT) and to assess the clinical outcomes in two different types of mesh in robotic Rives-Stoppa (rRS) ventral hernia repair (VHR).
Methods: A retrospective analysis of a robotic VHR database between February 1, 2013 and May 31, 2022. Patients who underwent a rRS VHR were included in this study and separated into two groups depending on the mesh used: Synecor Preperitoneal Biomaterial (Synecor Pre) and Bard™ Soft.
Quality of life and surgical outcomes of robotic retromuscular ventral hernia repair using a new hybrid mesh reinforcement.
Hernia
June 2022
Good Samaritan Medical Center, One Pearl Street, Brockton, MA, 02301, USA.
Purpose: The purpose of this study is to prospectively evaluate surgical and quality of life (QoL) outcomes of robotic retromuscular ventral hernia repair (rRMVHR) using a new hybrid mesh in high-risk patients.
Methods: Data was prospectively collected for patients classified as high-risk based on the modified ventral hernia working group (VHWG) grading system, who underwent rRMVHR using Synecor™ Pre hybrid mesh in a single center, between 2019 and 2020. Pre-, intra- and postoperative variables including hernia recurrence, surgical site events (SSE), hernia-specific quality of life (QoL), and financial costs were analyzed.
Comparative differences of mitral valve-in-valve implantation: A new mitral bioprosthesis versus current mosaic and epic valves.
Catheter Cardiovasc Interv
February 2022
Cardiovascular Masters Consortium, Durham, North Carolina, USA.
Objective: Evaluate transcatheter mitral valve replacement (TMVR) valve-in-valve (VIV) outcomes in three different mitral bioprostheses (of comparable measured internal diameters) under stable hemodynamic and surgical conditions by bench, echocardiographic, computerized tomography (CT), and autopsy comparisons pre- and post-valve implantation in a porcine model under matched controlled conditions.
Background: Impact of surgical bioprosthesis design on TMVR VIV procedures is unknown.
Methods: Fifteen similar-sized Yorkshire pigs underwent pre-procedural CT screening.
Comparison of a new bioprosthetic mitral valve to other commercially available devices under controlled conditions in a porcine model.
J Card Surg
December 2021
Cardiovascular Masters Consortium, Durham, North Carolina, USA.
Background/aim: To evaluate three mitral bioprostheses (of comparable measured internal diameters) under controlled, stable, hemodynamic and surgical conditions by bench, echocardiographic, computerized tomography and autopsy comparisons pre- and postvalve implantation.
Methods: Fifteen similar-sized Yorkshire pigs underwent preprocedural computerized tomography anatomic screening. Of these, 12 had consistent anatomic features and underwent implantation of a mitral bioprosthesis via thoracotomy on cardiopulmonary bypass (CPB).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!